FIG. 2.

Binding of MV-N to cells expressing FcγRII and another cell surface receptor. (A) Cell surface expression of N on living MV-infected TEC. TEC were infected with Edmonston MV strain at 0.1 PFU/cell. At different times postinfection, MV-N cell surface detection was determined by flow cytometry analysis with anti-MV-N (Cl25) and streptavidin-PE. The results are representative of six different experiments. (B) FcγRII expression on murine IIA1.6, on IIA1.6 expressing human FcγRIIb1, and on human TEC cell lines was detected by using anti-CD32-PE. For IIA1.6 and TEC, isotypic control and anti-CD32-PE are totally superimposed. (C) MV-N binding was detected with specific biotinylated anti-MV-N (Cl25) and then revealed with streptavidin-PE prior to flow cytometry analysis. Cells were incubated with 5 μg of purified recombinant MV-N in the absence (heavy line) or in the presence (thin line) of human blocking KB61 MAb. As a negative control, cells were incubated without MV-N in the presence of anti-MV-N (Cl25) and streptavidin-PE (dotted line). For IIA1.6 and TEC, the fluorescence intensity obtained in the presence of KB61 MAb superimposes on that obtained in the absence of this MAb. The results are representative from one of three independent experiments.